New FDA Rules Require More Minorities in Clinical Trials
By Radiant Health EditorsPublished: April 17, 2022
The FDA will now require companies to file a “race and ethnic diversity plan” with the agency when working on clinical development for treatments. The new regulations for pharmaceutical and medical device companies will increase the number of Black individuals as well as other underrepresented minorities in their clinical trials. People from disadvantaged populations and diverse backgrounds are often left out because of factors like religious affiliation, illiteracy, a lack of knowledge about clinical trials, and a suspicion of medical professionals. The FDA’s Office of Minority Health and Health Equity will help companies to meet the new guidelines.
Like what you're reading? Sign up for our free newsletter and never miss a post! Plus get a FREE digital version of our Issue No.10 with sign up.
- Coconut Cauliflower Rice With Jerk Chicken - November 29, 2024
- Protein Cottage Cheese Pancakes - November 27, 2024
- How To Reduce Screen Time On Phone: 5 Helpful Strategies To Help You Stay Connected With The Real World - October 30, 2024
- 11 Wellness Gift Ideas: Perfect Presents for Her that Nurture Body, Mind, and Soul - October 13, 2024
- 11 Best Indoor Air Purifying Plants: Nature’s Air Filters for Your Home - September 27, 2024
- 11 Best Health and Wellness Books to Read in 2025 - July 4, 2024
- Some Americans Will Have Medical Debt Wiped From Credit - July 9, 2022
- Natural Gas Used to Heat Homes Contains Some Harmful Chemicals - July 9, 2022
- Uterine Cancer Claims Many Black Lives - July 9, 2022
- Babies and Toddlers Get COVID-19 Shots - June 27, 2022